周翔医生简介

周翔，男，医学博士，主任医师，博士生导师，德国及瑞士博士后研究员，现任国家癌症中心/国家恶性肿瘤临床医学研究中心/北京协和医学院 中国医学科学院肿瘤医院介入治疗科副主任。是国内少有的同时掌握介入放射技术与超声介入技术的复合型两栖专家。从事恶性肿瘤的临床诊疗工作近20年，精通鼻咽肿瘤、甲状腺肿瘤、乳腺肿瘤、肺部肿瘤、肝脏肿瘤、胰腺肿瘤、泌尿肿瘤、妇科肿瘤、骨肿瘤及一些疑难罕见肿瘤的血管介入治疗、消融治疗、放射性粒子植入治疗、超声诊断、影像引导下活检及引流。提倡对恶性肿瘤进行多学科模式下的综合管理，对介入治疗联合靶向治疗及免疫治疗（PD-1、CTLA-4等）的综合治疗模式具有很深的造诣。现任北京肿瘤学会理事，北京肿瘤学会介入治疗专业委员会常委，中国超声医学工程学会介入青年委员会副主任委员，中华医学会超声医学会全国委员，中华医学会超声介入学组全国委员，北京乳腺病防治学会肿瘤免疫治疗专业委员会常委，中国超声医学工程学会超声治疗专业委员会常务委员。承担多项国家级科研课题，在国际顶级影像学杂志《Radiology》等发表多篇有影响的科研论文，并获颁多项国家发明专利。

中国抗癌协会肿瘤消融专委会常务委员
北京市肿瘤协会理事
北京市肿瘤协会介入分委会常务委员
科技部国家重点研发计划数字诊疗装备研发专项"新型专科超声成像系统、创新诊疗装备产品评价"评审专家
国家食品药品监督管理总局医疗器械技术创新医疗器械特别审批专家
北京市乳腺病防治学会肿瘤免疫治疗专业委员会常委
中国医学装备协会超声装备分会常委
中国医学装备人工智能联盟常委
中国超声医学工程学会青年委员会副主任委员
中国超声医学工程学会超声治疗专业委员会常委
中国超声医学工程学会超声分子影像专业委员会常委
中华医学会超声医学分会介入诊疗超声学组委员

四川省省杰出青年奖

在国际顶级医学影像科研期刊发表多篇专著，授权多项国家发明专利。
1. 授权国家发明专利（第一发明人）成果名称：一种靶向释放微量元素的药物组合物及制备方法和应用。授权国家发明专利号：ZL 201010223282.3。
2. 授权国家发明专利（第一发明人）成果名称：用于超声扫描的透声性和弹性良好的软性贴附固定装置。授权国家发明专利号：ZL201510926532.2
3. 授权国家发明专利（第一发明人）成果名称：定向控释微量元素的药物组合物及制备方法和应用；授权国家发明专利号：ZL201110277839.6。
4. 授权国家发明专利（第一发明人）成果名称：一种定量测定透析再循环的系统 。授权国家发明专利号 ZL200910107958.X。
5. 授权国家发明专利（第一发明人）成果名称：一种适于超声-CT/MRI/PET等融合成像的非侵入性标准配准装置。授权国家发明专利号： ZL201210312521.1。
6. 授权国家发明专利（第一发明人）成果名称：授权国家发明专利, 亲水－亲脂小体液相核心空化技术。授权国家发明专利号：ZL200410060609.4。
7. 主编 人民卫生出版社全国十三五研究生教材 《腹部超声诊断学》2019年出版
8. 主译 人民卫生出版社 《超声引导下肝脏外科解剖图谱》2016年出版
以下国际期刊论文均为：通讯作者或第一作者
9. Jiaxin Liu, Xiang Zhou.. Research on detection method of bleeding point in two-dimensional DSA image based on parametric color imaging. Computers in Biology and Medicine 2022, in press.
10. Yang Y, Zhou Y, Zhang X, et al. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma. 2021;8:837-850. Published 2021 Jul 28. doi:10.2147/JHC.S308587
11. Yang Y, Chen Y, Zhang X, et al. Predictors and patterns of recurrence after radiofrequency ablation for hepatocellular carcinoma within up-to-seven criteria: A multicenter retrospective study. Eur J Radiol. 2021;138:109623. doi:10.1016/j.ejrad.2021.109623
12. Chen Y, Yang Y, Zhang XY, et al. Nomogram Based on Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio to Predict Recurrence in Patients with Hepatocellular Carcinoma after Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2021;44(10):1551-1560. doi:10.1007/s00270-021-02872-8
13. Xin Y, Zhang X, Yang Y, et al. Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. J Gastrointest Oncol. 2021;12(6):2930-2942. doi:10.21037/jgo-21-506
14. Yang Y, Chen Y, Ye F, et al. Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival. Eur Radiol. 2021;31(5):3053-3064. doi:10.1007/s00330-020-07460-x
15. Xin Y, Zhang X, Li Y, et al. A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2022;45(1):43-53. doi:10.1007/s00270-021-02965-4
16. Chen Y, Yang Y, Xu WJ, et al. Clinical application of interventional embolization in tumor-associated hemorrhage. Ann Transl Med. 2020;8(6):394. doi:10.21037/atm.2020.03.69
17. Yang Y, Xin Y, Ye F, et al. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia. 2021;38(1):437-446. doi:10.1080/02656736.2020.1849828
18. Xin Y, Zhang X, Yang Y, et al. A multicenter, hospital-based and non-inferiority study for diagnostic efficacy of automated whole breast ultrasound for breast cancer in China. Sci Rep. 2021;11(1):13902. Published 2021 Jul 6. doi:10.1038/s41598-021-93350-1
19. Cao X, Liu Z, Zhou X, et al. Usefulness of real-time contrast-enhanced ultrasound guided coaxial needle biopsy for focal liver lesions. Abdom Radiol (NY). 2019;44(1):310-317. doi:10.1007/s00261-018-1713-y
20. Chen Y, Zhao C, Yang Y, et al. Using the Controlling Nutritional Status (CONUT) Score for Evaluating Patients with Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation: A Two-Center Retrospective Study. Cardiovasc Intervent Radiol. 2020;43(9):1294-1304. doi:10.1007/s00270-020-02519-0
21. Zhu W, Mai G, Zhou X, Song B. Double contrast-enhanced ultrasound improves the detection and localization of occult lesions in the pancreatic tail: a initial experience report. Abdom Radiol (NY). 2019;44(2):559-567. doi:10.1007/s00261-018-1746-2
22. Zhu W, Qing X, Yan F, Luo Y, Li Y, Zhou X. Can the Contrast-Enhanced Ultrasound Washout Rate Be Used to Predict Microvascular Invasion in Hepatocellular Carcinoma?. Ultrasound Med Biol. 2017;43(8):1571-1580. doi:10.1016/j.ultrasmedbio.2017.04.003
23. Wang L, Feng L, Rong W, et al. Regional Ischemic Preconditioning Has Clinical Value in Cirrhotic HCC Through MAPK Pathways. J Gastrointest Surg. 2019;23(9):1767-1777. doi:10.1007/s11605-018-3960-1
24. Xiachuan Q, Xiang Z, Xuebing L, Yan L. Predictive Value of Contrast-enhanced Ultrasound for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection. Ultrason Imaging. 2019 Jan;41(1):49-58.
25. Zhang X, Lin X, Tan Y, Zhu Y, Wang H, Feng R, Tang G, Zhou X, Li A, Qiao Y. A multicenter hospital-based diagnosis study of automated breast ultrasound system in detecting breast cancer among Chinese women. Chin J Cancer Res. 2018 Apr;30(2):231-239.
26. Zhao WP, Zhang J, Han ZY, Yao JP, Zhou X, Liang P. A clinical investigation treating different types of fibroids identified by MRI-T2WI imaging with ultrasound guided high intensity focused ultrasound. Sci Rep. 2017 Sep 7;7(1):10812.
27. Zhu W, Qing X, Yan F, Luo Y, Li Y, Zhou X. Can the Contrast-Enhanced Ultrasound Washout Rate Be Used to Predict Microvascular Invasion in Hepatocellular Carcinoma? Ultrasound Med Biol. 2017 Aug;43(8):1571-1580. doi: 10.1016/j.ultrasmedbio.2017.04.003. Epub 2017 May 11. PMID: 28502665.
28. Zhao WP, Han ZY, Zhang J, Yu XL, Cheng ZG, Zhou X, Liang P. Early experience: high-intensity focused ultrasound treatment for intra-abdominal aggressive fibromatosis of failure in surgery. Br J Radiol. 2016 Jun;89(1062):20151026. doi: 10.1259/bjr.20151026. Epub 2016 Apr 7. PMID: 27052682; PMCID: PMC5258167.
29. Feng Y, Qin XC, Luo Y, Li YZ, Zhou X. Efficacy of contrast-enhanced ultrasound washout rate in predicting hepatocellular carcinoma differentiation. Ultrasound Med Biol. 2015 Jun;41(6):1553-60. doi: 10.1016/j.ultrasmedbio.2015.01.026. Epub 2015 Mar 5. PMID: 25747937.
30. Jiang T, Chen F, Zhou X, Hu Y, Zhao Q. Percutaneous Ultrasound-Guided Laser Ablation with Contrast-Enhanced Ultrasonography for Hyperfunctioning Parathyroid Adenoma: A Preliminary Case Series. Int J Endocrinol. 2015;2015:673604. doi: 10.1155/2015/673604. Epub 2015 Dec 16. PMID: 26788059; PMCID: PMC4695663.
31. Zhou X, Yan F, Luo Y, Peng YL, Parajuly SS, Wen XR, Cai DM, Li YZ. Characterization and diagnostic confidence of contrast-enhanced ultrasound for solid renal tumors. Ultrasound Med Biol. 2011 Jun;37(6):845-53. doi: 10.1016/j.ultrasmedbio.2011.02.015. Epub 2011 May 5. PMID: 21546153.
32. Zhou X, Liu JB, Luo Y, Yan F, Peng Y, Lin L, Zhuang H. Characterization of focal liver lesions by means of assessment of hepatic transit time with contrast-enhanced US. Radiology. 2010 Aug;256(2):648-55. doi: 10.1148/radiol.10090715. PMID: 20656845.
33. Zhou X, Luo Y, Peng YL, Cai W, Lu Q, Lin L, Sha XX, Li YZ, Zhu M. Hepatic perfusion disorder associated with focal liver lesions: contrast-enhanced US patterns--correlation study with contrast-enhanced CT. Radiology. 2011 Jul;260(1):274-81. doi: 10.1148/radiol.11101454. Epub 2011 Apr 5. PMID: 21467250.